TY - JOUR T1 - BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants JF - medRxiv DO - 10.1101/2022.05.10.22274906 SP - 2022.05.10.22274906 AU - Annika Rössler AU - Antonia Netzl AU - Ludwig Knabl AU - Helena Schäfer AU - Samuel H. Wilks AU - David Bante AU - Barbara Falkensammer AU - Wegene Borena AU - Dorothee von Laer AU - Derek Smith AU - Janine Kimpel Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/10/2022.05.10.22274906.abstract N2 - Background Several studies have shown that SARS-CoV-2 BA.1 omicron is an immune escape variant and current vaccines and infection with pre-omicron variants provide limited protection against BA.1. Meanwhile, however, omicron BA.2 has become the dominant variant in many countries and has replaced BA.1. As BA.2 has several mutations especially in the receptor binding and the N terminal domain compared to BA.1, we analyzed whether BA.2 shows further immune escape relative to BA.1.Methods We characterized neutralization profiles against the new BA.2 omicron variant in plasma samples from a variety of individuals with different numbers of exposures to infection/vaccination, including samples from previously virus-naïve, BA.2 omicron-infected individuals. To illustrate antigenic differences of the two omicron sub-variants and pre-omicron variants we performed antigenic cartography and generated antibody landscapes.Results Unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and to BA.1. Consequently, our antigenic map, which included all Variants of Concern and both BA.1 and BA.2 omicron sub-variants, showed that both omicron sub-variants are distinct to pre-omicron variants, but that the two omicron variant are also antigenically distinct from each other. The antibody landscapes illustrate that cross-neutralizing antibodies against the whole antigenic space, as described in our maps, are generated only after three or more exposures to antigenically close variants but also after two exposures to antigenically distinct variants.Conclusions Here, we describe the antigenic space inhabited by the relevant SARS-CoV-2 variants, the understanding of which will have important implications for further vaccine strain adaptations.Competing Interest StatementDB declares to hold stocks of Pfizer. All other authors declare no conflicts of interest.Funding StatementJK was supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 101016174 and the Austrian Science Fund (FWF) with the project number P35159-B. DS was supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee (EC) of the Medical University of Innsbruck has approved the study with EC numbers: 1100/2020, 1111/2020, 1330/2020, 1064/2021, 1093/2021, 1168/2021, 1191/2021, and 1197/2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -